Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Taxotere Stories

2014-02-20 08:31:11

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Summary GBI Research has released the pharmaceutical report "Prostate Cancer Therapeutics Market to 2019 - Rising...

2012-10-25 07:31:17

PARIS, Oct. 25, 2012 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2012 Change on a reported Change at 9-month 2012 Change on a reported basis basis Change at constant constant exchange rates(1)...

2012-10-11 19:21:32

CHICAGO, Oct. 11, 2012 /PRNewswire-iReach/ -- Buffalo Grove, Illinois-based specialty-oncology drug development company, Meridian Laboratories, Inc is pleased to announce that the US Food and Drug Administration (FDA) has granted Meridian's request for a Type B Pre-Investigational New Drug (pre-IND) meeting to discuss its plan to commence clinical trials of ML061 as a treatment for various cancer indications. The meeting is scheduled for January 23, 2012 Meridian's lead product, ML061, is...

2012-07-26 02:29:02

PARIS, July 26, 2012 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q2 2012 Change on a Change at H1 2012 Change on a Change at reported constant reported constant basis exchange rates(1) basis exchange rates ----- ---------------- ----- -------------- Net sales...

2012-04-27 02:25:48

PARIS, April 27, 2012 /PRNewswire/ -- (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Q1 2012 Change on a Change at constant reported basis exchange rates -------------- -------------- Net sales euro 8,511m +9.4% +7.0% Business net income(1) euro 2,442m +12.5% +8.4%...

2012-02-08 06:00:00

PARIS, Feb. 8, 2012 /PRNewswire/ -- (Logo : http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Change at Change at Q4 2011 Change on a constant 2011 Change on a constant ------- ----------- --------- ---- ----------- --------- reported...

2011-11-03 06:30:00

PARIS, Nov. 3, 2011 /PRNewswire/ -- (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Change at Change at Change on a constant Change on a constant reported exchange 9 months reported exchange Q3 2011 basis rates 2011 basis rates...

2011-10-26 07:00:00

SAN DIEGO, Oct. 26, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it met with the U.S. Food and Drug Administration (FDA) to discuss a single clinical study to support approval of ANX-514 (docetaxel for injectable emulsion), a detergent-free reformulation of Taxotere (docetaxel). ADVENTRX proposed a non-inferiority study (Study 514-02) with a primary objective of comparing fluid retention following treatment with ANX-514, administered...

2011-07-28 06:00:00

PARIS, July 28, 2011 /PRNewswire/ -- (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Change on Q2 2011 a Change at ------- Reported Constant exchange basis rates(1) euro Net sales 8,349m +0.5% +6.9%...

2011-04-28 06:30:00

PARIS, April 28, 2011 /PRNewswire/ -- Change on a reported Q1 2011 basis Change Change at CER(2) excluding A/H1N1 ------- ----------- at CER(2) sales --------- ----------------- Net sales euro 7,779m -1.5%...